1Lyonel G Israels,Esther D Israels.Mechanism in Hematology[M].Core Health Services Inc,2002:346-353
2Lijnen HR.Molecular interactivions detween the plasminogen/plasmin and matrix metalloproteinase systems[J].Fibrinolysis Proteolysis,2000,14:175
3Kanse SM,Chavakis T,Kuo A,et al.Variability in the expression of Urokinase receptor(CD87) mutants on cell; relevance to cell adhesion[J].Cell Biochem Funct,2004,22 (4):257-264
4Chorostowska Wynimko J,Skrzypczak Jankun E,Jankun J,et al.Plasminogen activator inhibitor type-1:its structure,biological activity and role in tumorigenesis[J].Int J Mol Med,2004,13(6):759-766
6Nicholl SM,Roztocil E,Davies MG,et al.Plasminogen activator system and vascular disease[J].Current Vascular Pharmacology,2006,4(2):101-116
7Jost M,Folgueras AR,Pendas AM,et al.Earlier onset of tumoral angiogenesis in matrix metalloproteinase deficient mice[J].Cancer Research,2006,66 (10):5234-5241
8Mook OR,Frederiks WM,Van Noorden CJ,et al.The role of gelatinases in colorectal cancer progression and metastasis[J].Biochim Biophys Acta,2004:1705(2):69-89
9Moran A,Iniesta P,Garcia-Aranda C,et al.Clinical relevance of MMP-9,MMP-2.TIMP-1,and TIMP-2 in colorectal cancer[J].Oncol Rep,2005,13(1):115-120
10Hsu CP,Shen GH,Ko JK,et al.Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer[J].Lung Cancer,2006,52(3):349-357
二级参考文献43
1Campochiaro PA, Soloway P, Ryan SJ, et al. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis, 1999,5:34-38.
2Hartnett ME, Lappas A, Darland D, et al. Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp Eye Res, 2003, 77:593-599.
3Nicolo M, Piccolino FC, Zardi L, et al. Detection of tenascin-C in surgically excised choroidal neovascular membranes. Graefes Arch Clin Exp Ophthalmol, 2000, 238:107-111.
4Nicolo M, Biro A, Cardillo-Piccolino F, et al. Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes. Am J Ophthalmol, 2003, 135:7-13.
5Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem, 1999, 74 :135-143.
6Shen WY, Yu MJ, Barry CJ, et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol, 1998,82:1063-1071.
7Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.Invest Ophthalmol Vis Sci, 2003, 44:2743-2749.
8Das A, McGuire PG. Retinal and choroidal angiogenesis:pathophysiology and strategies for inhibition. Prog Retin Eye Res, 2003, 22:721-748.
9Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovaseular diseases. Proc Natl Acad Sci USA, 1996, 93:9764-9769.
10Kamizuru H, Kimura H, Yasukawa T, et al. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci, 2001, 42:2664-2672.
2Chavakis T, Kanse SM, Yutzy B, et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor- urokinase complexes. Blood, 1998, 91:2305.
3Jorvanori ZB,Ilic M.PAi-1 in the evolution of stroke[J].Srp Arh Celok,2004,132(5-6):143-147.
4Song SJ,Hu JB,Wang Hx,et al.expression of u-PA and its receptor in plasma of with cerbral icfaraction[J].Zhonghua Yi Xue Za Zhi,2003,83(18):583-585.
5X.-G.LU,J.-S.MAO,J.-F.TONG,et al.Fibrinolytic characteristics and their significance in malignant,tuberculous and cirrhotic pleural and ascitic fluids[J].International Journal of Laboratory Hematology,2007,29(1):132-138.
6Chavakis T,Kanse SM,Yutzy B,et al.Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes[J].Blood,1998,91:2305-2312.
7Zhou H, Wu X, Lu X, et al. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogenactivator receptor in patients with acute and chronic hepatitis B [J]. Thromb Res, 2009,123(3) :537-542.
8Mustjoki S, Alitalo R, Stephens RW, et al. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classfication and response to therapy[J]. Thromb Haemost, 1999,81 ( 5 ) : 705-710.
9Chavakis T, Kanse SM, Yutzy B, et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes [ J ]. Blood, 1998, 91 (7) : 2305-2312.
